The loss of Rigel Pharmaceuticals under GAAP for the 3 months of 2022 was $27.445 million, against a profit of $39.5 million in the previous year. Revenue decreased 4.8 times to $16.735 million from $81.018 million the year before.
The loss of Rigel Pharmaceuticals under GAAP for the 3 months of 2022 was $27.445 million, against a profit of $39.5 million in the previous year. Revenue decreased 4.8 times to $16.735 million from $81.018 million the year before. 
rigel.com
English (US) 